Cary, North Carolina—CPESN USA announces the expansion of their strategic relationship with Genemarkers, LLC, a pharmacogenomic (PGx) testing laboratory in Michigan. Through this national program, CPESN pharmacies identify patients that would benefit from PGx testing, collect patient DNA samples via a buccal swab and review the results with their patient and the health care provider. This personalized medicine tool determines if a medication will be safe and efficacious. PGx testing has been proven to reduce adverse drug events and improve health outcomes.
“We are excited to be moving forward with the team from Genemarkers,” said Alison Haas, Pharm.D., Director of Value-Based Programs with CPESN USA. “They have been working collaboratively with our pharmacies in their home state of Michigan for the past year. Now, we are launching a similar program across the rest of our local networks.”